DNA Stock Analysis
DN
Uncovered
Ginkgo Bioworks Holdings Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.378
Dividend yield
—
Shares outstanding
1 709.12 B
Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 1,292 full-time employees. The company went IPO on 2021-04-19. The firm's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products such as therapeutics, key food ingredients, and chemicals derived from petroleum. The firm operates through two segments: Foundry and Biosecurity. Foundry consists of research and development services performed under collaboration and license agreements relating to the Company’s cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics, which is paired with the Company’s Codebase, a collection of biological parts and a database of biological data used to program cells. Biosecurity consists of COVID-19 testing products and services primarily provided to public health authorities.